Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BActinium-2: [225Ac]Ac-AKY-2519 in B7-H3 Positive Solid Tumors
NCT07887971Phase 1Recruiting
- Sponsor
- Aktis Oncology
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AKY-2519 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), prostate cancer (PCa) and 3 more, sponsored by Aktis Oncology. Primary endpoints: Adverse Events at 30 days, Dose-Limiting Toxicity at 28 days and 1 more. Started Nov 2026; status: recruiting.
02
Drugs
AKY-2519
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)prostate cancer (PCa)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07887971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887971.